Individuals Stopping Weight-Loss Injections Gain Back Weight Four Times Faster Compared to Those on Conventional Diets

Fresh analysis reveals that individuals who discontinue blockbuster slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans.

Published data in a major medical journal points out that while overweight people can lose substantial amounts of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.

"Users using such drugs must be aware of the potential of rapid weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.

This pace of recovery suggests a return to pre-treatment weight within about 18 months.

Weighing Treatments

The analysis, which reviewed dozens of studies involving thousands of patients, compared the outcomes of the injectable medications with other pills.

The team point out that people who lose weight through dieting typically see a more gradual creep back—perhaps 100 grams monthly—post-intervention.

Understanding the Fast Regain

Doctors suggest the mode of action of the drugs accounts for the heightened rebound.

GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate appetite.

"Long-term administration of the hormone levels several times higher than normal could lead to the body to produce less of its endogenous GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this medication results in hunger is no longer kept in check, making binge eating much more probable."

An Ongoing Condition?

Health authorities recommend the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.

Many experts say that, considering the high risk of weight regain, the therapy should be considered ongoing.

This view is echoed by drug manufacturers, who note that the findings "emphasize the long-term character of obesity," comparing it to managing conditions like diabetes.

Patient Accounts

People who have come off the jabs describe a powerful return of cravings.

"It was like a switch that goes on and I was suddenly extremely hungry," recalled one woman.

This difficulty is exacerbated if patients have not established lasting dietary or behavioural modifications during treatment.

Significant Adoption

Survey data show that millions of adults in the UK have used these injections in the past year, with desire remaining high.

• Use is greater among women than men.
• The middle-aged demographic shows the greatest usage rates.
• A large proportion obtain the drugs through private prescriptions rather than public health services.

Finally, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent solution and lasting health benefits likely depends on integrated lifestyle changes.